Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 34Leiomyoma 12Menorrhagia 5Endometriosis 4Myofibroma 3Prostate Adenocarcinoma 2Pregnancy Complications 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Hemorrhage 1Pathologic Complete Response 1Neoplasm, Residual 1Neoplasm Metastasis 1Myoma 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-Resistant Prostate Cancer 1Hormone Treatment-naïve Participants With Prostate Cancer 1

Interventions

enzalutamide 7Abiraterone Acetate 4abiraterone 3Prednisone 3Docetaxel 3sapanisertib 1relugolix 1pembrolizumab 1onvansertib 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1apalutamide 1abemaciclib 1Prednisolone 1PF06821497 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer × relugolix × Clear all
NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡